Feature | October 09, 2013

PET-CT Improves Care of Limited-Stage Small-Cell Lung Cancer Patients

Researchers find improved overall survival for LS-SCLC patients

October 9, 2013 — Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease. These patients are often treated with chemotherapy and definitive radiation therapy. Staging information is essential because of the high propensity for metastatic disease in SCLC, and the identification of metastases can spare patients from the toxicity associated with thoracic radiotherapy. Furthermore, in those patients who do receive radiotherapy, knowing the exact extent of disease may permit more accurate treatment volume delineation.

Until 2011, the National Comprehensive Cancer Network (NCCN) recommended a bone scan as part of the initial evaluation of all newly diagnosed SCLC patients. However, in 2012, the NCCN began recommending positron emission tomography computed tomography (PET-CT) in lieu of bone scan. Researchers from the University of Pennsylvania wanted to know the clinical impact of using PET instead.

A study published in the July issue of the Journal of Thoracic Oncology (JTO), concluded that PET-CT improves staging accuracy and intrathoracic disease identification, which translates into an improvement in clinical outcome in these patients.

"Pretreatment PET staging of LS-SCLC was associated with improved survival," reported the authors. "PET-staged patients had an improved three-year overall survival from diagnosis (47 percent versus 19 percent) compared with those with LS-SCLC who were not staged with PET." The lead author of this work was Eric Xanthopoulos, M.D. International Association fort the Study of Lung Cancer (IASLC) co-authors included Corey Langer, Charles Simone and Ramesh Rengan.

For more information: www.iaslc.org

Related Content

Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
A University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows an important predictor of PET-CT use

Rustain Morgan, M.D., and colleagues show racial/ethnic disparities in use of important imaging during lung cancer diagnosis. Photo courtesy of University of Colorado Cancer Center

News | PET-CT | March 12, 2020
March 12, 2020 — The use of PET-CT
MR Solutions’ dry magnet MRI system for molecular imaging on display at EMIM 2020
News | Magnetic Resonance Imaging (MRI) | February 28, 2020
February 28, 2020 — MR Solutions will be displaying its la
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

News | PET-CT | November 15, 2019
November 15, 2019 — According to an article published ahead-of-print in the...